For the third quarter of fiscal year ending December 2026, consolidated revenue totaled 783,978 thousand USD (YoY comparison unknown). Operating loss was -8,437,219 thousand USD, and net loss attributable to owners of parent for the quarter was -7,743,359 thousand USD. Full-year forecast for fiscal 2026 has not been disclosed. Cash was 29.3 million USD and working capital was 26.8 million USD. The company continues to pursue capital-raising measures including a SEPA with Yorkville.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4875-20261113-01.pdf","jir_short_summary":"For the third quarter of fiscal year ending December 2026, consolidated revenue totaled 783,978 thousand USD (YoY comparison unknown). Operating loss was -8,437,219 thousand USD, and net loss attributable to owners of parent for the quarter was -7,743,359 thousand USD. Full-year forecast for fiscal 2026 has not been disclosed. Cash was 29.3 million USD and working capital was 26.8 million USD. The company continues to pursue capital-raising measures including a SEPA with Yorkville.","jir_summary":"### Performance Overview\nDuring the period, revenue reached 783,978 thousand USD, while operating loss amounted to -8,437,219 thousand USD and quarterly net loss was -7,743,359 thousand USD. Although research and development expenses were restrained to some extent, the company remained in an overall loss position. Cash and cash equivalents were 29.3 million USD, and shareholders' equity was reported as 41.094 hundred million USD, indicating continued pressure on the capital structure. The outlook for the next fiscal year has not been announced and may change depending on progress in partnership and out-licensing activities.\n\n### Outlook and Capital Strategy\nThe financial summary does not include consolidated earnings guidance for the fiscal year ending December 2026, and notes that the portion of R&D expenses borne may fluctuate depending on the terms of collaboration agreements. As a capital policy, the company maintains a framework to utilize a SEPA with Yorkville and the sale of common stock through Lucid, with costs and fees associated with issuance and sale of shares being incurred.","jir_financial_highlights":"Revenue: 783,978 (Year-over-Year comparison unknown)\nOperating Income: - 8,437,219 (Year-over-Year comparison unknown)\nNet Income Attributable to Owners of Parent: - 7,743,359 (Year-over-Year comparison unknown)\nCash and Cash Equivalents: 29,256,294 (Decreased from prior fiscal year-end)\nShareholders' Equity: 41,094,498 (Decreased from prior fiscal year)","jir_category":"","jir_hashtags":"#MediciNovaInc, #Earnings, #USGAAPFinancials","jir_key_figures":"Revenue: 783,978 (thousand USD)\nOperating Income: -8,437,219 (thousand USD)\nNet Income Attributable to Owners of Parent: -7,743,359 (thousand USD)","jir_meta_title":"MediciNova, Inc. \u2014 Q3 Fiscal 2026 Quarterly Financial Summary | Revenue & Net Loss","jir_meta_description":"Summary of MediciNova, Inc.'s Q3 fiscal 2026 quarterly financial summary under U.S. GAAP. Includes revenue, operating loss, net loss, cash position, and capital strategy. Full-year outlook not disclosed.","jir_og_title":"MediciNova, Inc. | Q3 Fiscal 2026 Quarterly Financial Summary","jir_og_description":"MediciNova, Inc. Q3 results: revenue 783,978 thousand USD; net loss 7,743,359 thousand USD. Full-year forecast not disclosed. Capital strategy includes Yorkville SEPA.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-150886","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n